Plasma Fractionation Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Plasma Fractionation Market Share & Size. The Market is Segmented by Product (immunoglobulins, Platelets, Coagulation Factor Concentrate, Albumin, and Other Products), Application (Neurology, Immunology, Hematology, and Other Applications), End-User (hospitals and Clinics, Clinical Research Laboratories, and Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value in (USD Million) for the Above Segments.

Plasma Fractionation Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Plasma Fractionation Market Size

Plasma Fractionation Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 37.28 Billion
Market Size (2030) USD 51.85 Billion
CAGR (2025 - 2030) 6.82 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Plasma Fractionation Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Plasma Fractionation Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Plasma Fractionation Market Analysis

The Plasma Fractionation Market size is estimated at USD 37.28 billion in 2025, and is expected to reach USD 51.85 billion by 2030, at a CAGR of 6.82% during the forecast period (2025-2030).

During COVID-19, the convalescent plasma demand increased, as the doctors initially treated the patients affected by the virus with convalescent plasma. For instance, according to an article published by frontiers in June 2021, convalescent plasma was widely used worldwide to treat patients hospitalized with coronavirus and prevent disease progression. Studies revealed that convalescent plasma transfusion contributes to improved symptomatology and viral clearance. Thus, there was an increasing need for plasma fractions to treat the COVID-19 patient initially. As the pandemic has subsided and fewer people are getting infected with the virus, the studied market is expected to have stable growth during the forecast period of the study.

Specific factors driving the market growth include the growing use of immunoglobulins in various therapeutic areas, the rising geriatric population coupled with rising in the prevalence of rare diseases, and the increasing number of plasma collection centers across the globe. For instance, according to the WHO facts of October 2022, the global population proportion aged 60 and up will nearly double by 2050. By 2050, 80% of the world's elderly will live in low- and middle-income countries and are also said to be aging much faster than in the past. Hence, with the rising geriatric population, the burden of rare diseases is also expected to increase worldwide, increasing the adoption of plasma fractionation products and thus driving the growth of the studied market. Furthermore, according to an article updated by NCBI in August 2022, Von Willebrand's disease is estimated to affect approximately 1% of the population globally. Still, clinically significant disease prevalence is estimated to be about 125 per million, with severe disease affecting up to five per million. Hence, the rising geriatric population coupled with the increasing burden of rare diseases like Von Willebrand is anticipated to drive the demand for plasma fractionation products, thereby boosting the market growth.

Moreover, the increasing number of plasma collection centers around the globe is also a significant factor in the growth of the studied market. For instance, in April 2022, Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, opened its 29th plasma donation center. Furthermore, in October 2022, Freedom Plasma opened its fourth plasma donation center in Ohio, US. Hence, opening new plasma centers worldwide is expected to increase the production of plasma-based products, thus enhancing market growth.

Additionally, various activities by the key market players, such as product launches, partnerships, mergers, and acquisitions to bring technologically advanced plasma fractionation techniques and products into the market, are anticipated to boost the market. For instance, in January 2022, Octapharma received approval for expanding the indications of cutaquig in the European Union (EU). Cutaquig is a human immunoglobulin for subcutaneous administration. It provides flexible treatment options to many patients with acquired immune deficiencies.

Thus, factors such as the growing use of immunoglobulins in various therapeutic areas, the rising geriatric population coupled with rising in the prevalence of rare diseases, the increasing number of plasma collection centers, and various activities by the key market players are anticipated to boost the market over the forecast period. However, strict regulations for handling plasma protein products, high cost, and reimbursement issues restrain the market studied.

Plasma Fractionation Industry Overview

The plasma fractionation market is moderately competitive and consists of several major players. Companies like Bio Products Laboratory, China Biologic Products, CSL Behring, Grifols S.A., Takeda Pharmaceutical Company Ltd, Kedrion S.p.A, Octapharma, Shanghai RAAS Blood Products, among others, hold a substantial market share in the market. These significant companies in the market are engaging in partnerships, mergers, and acquisitions, aiming to strengthen their product portfolios and manufacturing capacities and provide competitive differentiation.

Plasma Fractionation Market Leaders

  1. CSL Behring

  2. Grifols S.A

  3. Octapharma

  4. Kedrion S.p.A

  5. Bio Products Laboratory

  6. *Disclaimer: Major Players sorted in no particular order
Plasma Fractionation Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Plasma Fractionation Market News

  • October 2022- Grifols inaugurated a new albumin purification and filling plant at its global manufacturing and supply hub in Dublin, Ireland.
  • September 2022- CSL Behring K.K. received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare of Japan for Berinert S.C. Injection 2000, a lyophilized human C1-esterase inhibitor concentrate for subcutaneous (SC) injection in plasma derivative, for the prevention of acute hereditary angioedema (HAE) attack.

Plasma Fractionation Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
    • 4.2.2 Rising Geriatric Population coupled with Rise in Prevalence of Rare Diseases
    • 4.2.3 Increasing Number of Plasma Collection Centers across the Globe
  • 4.3 Market Restraints
    • 4.3.1 Strict Regulations For the Handling of Plasma Protein Products
    • 4.3.2 Emergence of Recombinant Alternatives
    • 4.3.3 High Cost and Limited Reimbursement
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Immunoglobulins
    • 5.1.2 Platelets and Coagulation Factor Concentrates
    • 5.1.3 Albumin
    • 5.1.4 Other Products
  • 5.2 By Application
    • 5.2.1 Neurology
    • 5.2.2 Immunology
    • 5.2.3 Hematology
    • 5.2.4 Other Applications
  • 5.3 By End-User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Clinical Research Laboratories
    • 5.3.3 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bio Products Laboratory
    • 6.1.2 CBPO Group (China Biologic Products)
    • 6.1.3 CSL Behring
    • 6.1.4 Grifols S.A.
    • 6.1.5 Takeda Pharmaceutical Company Ltd
    • 6.1.6 Kedrion S.p.A
    • 6.1.7 Octapharma
    • 6.1.8 Shanghai RAAS Blood Products
    • 6.1.9 Sanquin
    • 6.1.10 LFB corporation
    • 6.1.11 GC Pharma
    • 6.1.12 PlasmaGen BioSciences Pvt. Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Plasma Fractionation Industry Segmentation

As per the scope of the report, plasma fractionation is defined as the general process of separating the various components of blood plasma obtained via blood fractionation. Plasma contains multiple proteins, including immunoglobulins, albumin, and coagulation proteins. The Plasma Fractionation Market is segmented by product (immunoglobulins, platelets, coagulation factor concentrate, albumin, and other products), application (Neurology, Immunology, Hematology, and other applications), end-user (hospitals and clinics, clinical research laboratories, and other end-users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in (USD million) for the above segments.

By Product Immunoglobulins
Platelets and Coagulation Factor Concentrates
Albumin
Other Products
By Application Neurology
Immunology
Hematology
Other Applications
By End-User Hospitals and Clinics
Clinical Research Laboratories
Other End-Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Plasma Fractionation Market Research FAQs

How big is the Plasma Fractionation Market?

The Plasma Fractionation Market size is expected to reach USD 37.28 billion in 2025 and grow at a CAGR of 6.82% to reach USD 51.85 billion by 2030.

What is the current Plasma Fractionation Market size?

In 2025, the Plasma Fractionation Market size is expected to reach USD 37.28 billion.

Who are the key players in Plasma Fractionation Market?

CSL Behring, Grifols S.A, Octapharma, Kedrion S.p.A and Bio Products Laboratory are the major companies operating in the Plasma Fractionation Market.

Which is the fastest growing region in Plasma Fractionation Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Plasma Fractionation Market?

In 2025, the North America accounts for the largest market share in Plasma Fractionation Market.

What years does this Plasma Fractionation Market cover, and what was the market size in 2024?

In 2024, the Plasma Fractionation Market size was estimated at USD 34.74 billion. The report covers the Plasma Fractionation Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Plasma Fractionation Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Plasma Fractionation Industry Report

The global plasma fractionation market is experiencing significant market growth, driven by the increasing demand for immunoglobulins and plasma-derived products used in treating various diseases such as respiratory conditions and Alpha-1 Antitrypsin Deficiency (AATD). This market growth is further supported by advancements in diagnostics, expansion of plasma collection centers, and strategic inventory management by key players. Despite facing challenges such as high costs and potential disruptions from recombinant alternatives, the industry sees opportunities in regions aiming for plasma fractionation self-sufficiency and policy revisions to boost domestic plasma product supply.

The industry analysis highlights the market segmentation by product, application, end-user, and geography, offering a comprehensive industry overview. The market size is segmented by immunoglobulins, platelets, coagulation factor concentrate, albumin, and other products. Applications span across neurology, immunology, hematology, and other fields, with end-users including hospitals and clinics, clinical research laboratories, and other entities. The industry reports provide detailed market data, market predictions, and market review, ensuring a thorough understanding of the industry's dynamics.

In terms of market forecast, the industry is poised for continued expansion, particularly focusing on immunoglobulins and coagulation factors. The market outlook is positive, with new market segments in neurology and beyond being tapped into. The industry research emphasizes the importance of strict regulations to ensure product safety and quality, which is crucial for maintaining market value and industry statistics.

The market leaders are adapting to these changes, and the market trends indicate a growing emphasis on regional self-sufficiency in plasma fractionation. The report example and report pdf from Mordor Intelligence™ Industry Reports offer a detailed analysis and free download for further insights. This industry information is vital for understanding the market segmentation and market value, providing a clear industry outlook and market overview.

Overall, the plasma fractionation market is set for significant growth, with a strong focus on industry sales and market segmentation. The market data and industry trends provide a comprehensive view of the market's potential, ensuring stakeholders are well-informed about the industry's direction and opportunities.